Equities

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.144
  • Today's Change-0.009 / -5.88%
  • Shares traded340.00k
  • 1 Year change-2.70%
  • Beta0.3160
Data delayed at least 15 minutes, as of Apr 30 2024 08:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shenzhen Neptunus Interlong Bio-Technique Company Limited is a Hong Kong-based company principally engaged in the development, production and sales of medicines. The Company operates through three segments. Medicines segment is engaged in the manufacture and sales of medicines. Medicines and Healthcare Products segment is engaged in the sales and distribution of medicines and healthcare products. Research and Development Services of Modern Biological Technology segment is engaged in the provision of research and development services of modern biological technologies, such as in vitro diagnostics reagents businesses. The products of the Company include herbal medicines, generic drugs, transfusion and anti-tumor drugs, among others. The Company mainly operates businesses in China.

  • Revenue in HKD (TTM)1.15bn
  • Net income in HKD26.06m
  • Incorporated1994
  • Employees1.44k
  • Location
    Shenzhen Neptunus Interlong Bio-technique Co Ltd1F, Block 1, Research BuildingNeptunus Technical CenterSHENZHEN 518000ChinaCHN
  • Phone+86 75 526411869
  • Fax+86 75 586391610
  • Websitehttps://www.interlong.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Huakang Biomedical Holdings Co Ltd26.61m-6.25m52.05m96.00--0.7896--1.96-0.015-0.0150.0640.13170.3742.702.57277,153.70-8.78-6.96-10.62-8.0164.2866.44-23.48-20.233.82--0.0429---2.77-3.00-88.03------
Extrawell Pharmaceutical Holdings Ltd68.62m-154.28m66.92m169.00--0.0643--0.9752-0.0776-0.07760.02090.43540.05387.479.89379,132.60-12.004.62-12.504.8847.3651.97-223.0773.993.38-0.05140.09680.00-1.82-3.28-1.0133.99121.54--
Regent Pacific Group Ltd2.48m-196.09m91.36m17.00------36.81-0.871-0.8710.011-0.05320.0218--12.19145,974.80-172.08-50.00-694.26-59.04-----7,901.89-2,685.21--------574.47-44.7231.24------
Sanai Health Industry Group Co Ltd131.90m20.13m95.56m68.004.010.28095.360.72450.00620.00620.03480.0890.3179188.037.641,939,746.003.482.314.723.6528.7734.8710.956.566.22--0.1881---30.6016.04-36.23------
China Health Group Inc23.15m-62.89m118.45m42.00--1.29--5.12-0.0632-0.06320.02330.09210.1438--0.246551,082.60-39.076.84-51.269.5238.3374.98-271.7019.19--------63.67-18.51-267.82------
BioSino Bio-technology and Science Inc312.29m-12.58m136.02m537.00--0.5985--0.4356-0.087-0.0872.161.570.49562.791.46581,538.40-3.30-3.84-8.55-10.1744.0640.17-6.66-6.980.9033--0.3956---22.52-0.9513-243.70---16.58--
Kontafarma China Holdings Ltd809.11m-28.84m167.66m720.00--0.15863.790.2072-0.0052-0.00520.1450.18920.42063.227.031,123,760.00-3.18-1.33-4.22-2.1858.2554.70-7.55-4.121.28-6.190.2392---9.50-17.3266.02------
Canbridge Pharmaceuticals Inc111.13m-409.26m176.31m100.00------1.59-0.9644-0.96440.2619-0.10120.18754.164.091,111,317.00-69.04---154.20--62.37---368.26--0.6132-41.341.39--30.26--21.64------
Modern Chinese Medicine Group Co Ltd371.70m52.71m189.00m191.003.590.373.190.50850.08790.08790.61950.85140.66815.453.781,946,099.009.4720.7610.7525.8230.2841.0214.1820.117.9838.180.0002---13.9114.67-44.440.2303----
Shenzhen Neptunus Intrlng Bi tchnq CoLtd1.15bn26.06m256.73m1.44k9.850.26174.930.22320.01550.01550.68560.58470.74373.036.51796,656.101.013.461.575.1341.8149.141.364.291.95--0.08110.007.924.19-55.60-12.89-11.10--
Wai Yuen Tong Medicine Holdings Limited1.36bn36.42m270.52m1.96k7.630.12151.580.1990.03030.03031.131.900.20140.42422.81700,208.600.8907-0.07331.54-0.119649.0842.524.42-0.4560.56631.490.31960.00-7.558.7581.16---12.06--
PuraPharm Corp Ltd406.86m-106.08m289.01m662.00--1.89--0.7103-0.2685-0.26851.030.38710.43741.044.19614,590.60-11.40-9.20-34.00-19.7053.2459.44-26.07-19.330.3046-2.280.7349---9.20-11.4111.76---13.68--
Hin Sang Group (Interntnl) Hldng Co Ltd92.79m-35.72m338.46m265.00--1.53--3.65-0.0327-0.03270.0850.2020.15242.299.49366,766.80-5.81-4.06-8.74-5.2655.9561.98-38.14-20.980.1129-1.150.5766---32.42-15.45-315.54---36.30--
Data as of Apr 30 2024. Currency figures normalised to Shenzhen Neptunus Interlong Bio-technique Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Invesense Asset Management Ltd.as of 29 Feb 202480.00k0.02%
Data from 29 Feb 2024 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.